Stem cell transplantation outcomes in lymphoblastic lymphoma

Area of Science:

• Hematology
• Oncology
• Transplant Medicine

Background:

• Lymphoblastic lymphoma (LBL) is an aggressive hematologic malignancy.
• LBL shares pathological similarities with lymphoblastic leukemia but presents primarily with nodal or extra-medullary disease.

Purpose of the Study:

• To evaluate the outcomes of patients with lymphoblastic lymphoma (LBL) undergoing stem cell transplantation (SCT).
• To compare current SCT outcomes for LBL against historical data.

Main Methods:

• Retrospective analysis of 39 patients with LBL who received SCT between 1990 and 2015.
• Data collected included type of SCT (allogeneic or autologous), remission status, conditioning regimens, and survival outcomes.

Main Results:

• Overall survival (OS) and progression-free survival (PFS) at three years were 41% for the cohort.
• Cumulative incidence of non-relapse mortality (NRM) was 18% at one year, and relapse mortality was 36% at three years.
• Multivariate analysis identified complete remission (CR) at the time of SCT and total-body irradiation (TBI)-based conditioning as independent predictors of improved OS and PFS.

Conclusions:

• Stem cell transplantation (SCT) outcomes for lymphoblastic lymphoma (LBL) are comparable to historical results.
• Achieving complete remission (CR) prior to SCT and utilizing total-body irradiation (TBI)-based conditioning in allogeneic SCT may enhance disease control and survival for LBL patients.